Publication | Closed Access

Idarubicin in sequential combination with cytosine arabinoside in the treatment of relapsed and refractory patients with acute non-lymphoblastic leukemia

Hematological MalignancyOncologySequential CombinationMedicineMixed-phenotype Acute LeukemiaHematologyMyeloid NeoplasiaMalignant Blood DisorderCytosine ArabinosidePharmacotherapyRefractory PatientsPharmacologyRadiation OncologyHealth Sciences